Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.14 EPS

Vir Biotechnology (NASDAQ:VIR) released its earnings results on Wednesday. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14, FiscalAI reports. The company had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.The business’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.80) EPS.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta efficacy data remained strong: In the 96-week SOLSTICE analysis, 88% of patients receiving elebsiran plus tobevibart achieved undetectable virus versus 53% with tobevibart alone, alongside durable ALT improvements and no treatment-related serious adverse events or discontinuations.
• Vir completed enrollment in all three registrational ECLIPSE studies, with topline data expected from ECLIPSE 1 in the fourth quarter of 2026 and ECLIPSE 2 and 3 in the first quarter of 2027. The company highlighted ECLIPSE 2’s bulevirtide-switch data as a potential launch differentiator.
• The oncology pipeline advanced rapidly following the Astellas collaboration, with VIR-5500 enrolling multiple monotherapy and combination expansion cohorts and potential phase III trials targeted for 2027. Additional data from HER2-targeted VIR-5818 are expected in the second half of 2026.
• Vir ended the quarter with approximately $1.01 billion in cash, cash equivalents, and investments after receiving $315 million from Astellas, extending projected cash runway into the second half of 2028.
• Management acknowledged ongoing senior leadership recruitment, including searches for a new chief medical officer and chief financial officer, while the company continues to manage simultaneous hepatitis delta and oncology development programs.

Vir Biotechnology Price Performance

Shares of NASDAQ VIR traded down $0.45 during trading on Thursday, reaching $8.66. 1,865,858 shares of the stock traded hands, compared to its average volume of 2,537,462. The stock has a market capitalization of $1.46 billion, a P/E ratio of -2.77 and a beta of 1.66. Vir Biotechnology has a 52-week low of $4.16 and a 52-week high of $11.66. The company has a 50-day moving average of $9.32 and a 200-day moving average of $9.02.

Insiders Place Their Bets

In related news, Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the sale, the director owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in shares of Vir Biotechnology by 2,088.4% in the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Vir Biotechnology in the 1st quarter worth approximately $359,000. Goldman Sachs Group Inc. boosted its holdings in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after buying an additional 225,544 shares during the period. Woodline Partners LP grew its stake in Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after buying an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth grew its stake in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after buying an additional 2,566 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VIR shares. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a report on Thursday. Wall Street Zen cut shares of Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Leerink Partners increased their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $20.62.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.